Nothing Special   »   [go: up one dir, main page]

CO6190608A2 - Sal de potasio cristalina de analogos de lipoxina a4 - Google Patents

Sal de potasio cristalina de analogos de lipoxina a4

Info

Publication number
CO6190608A2
CO6190608A2 CO09057912A CO09057912A CO6190608A2 CO 6190608 A2 CO6190608 A2 CO 6190608A2 CO 09057912 A CO09057912 A CO 09057912A CO 09057912 A CO09057912 A CO 09057912A CO 6190608 A2 CO6190608 A2 CO 6190608A2
Authority
CO
Colombia
Prior art keywords
potassium salt
lipoxine
formula
optionally substituted
substituents selected
Prior art date
Application number
CO09057912A
Other languages
English (en)
Inventor
Tilo Haag
Danja Grossbach
Gabriele Winter
Michael Sander
Wolfgang Beckmann
Klaus Bartel
Christian Dinter
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39076610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6190608(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CO6190608A2 publication Critical patent/CO6190608A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)

Abstract

1.- Una sal de potasio cristalina de la fórmula (I):en donde: R1 es -O-, -S(O)t- (donde t es 0, 1 ó 2), o una cadena de alquileno lineal o ramificada; y R2 es arilo (opcionalmente sustituido con uno o varios sustituyentes seleccionados de alquilo, alcoxi, halo, ha- loalquilo y haloalcoxi) o aralquilo (opcionalmente sustituido con uno o varios sustituyentes seleccionados de alquilo, alcoxi, halo, haloalquilo y haloalcoxi) y en donde el compuesto de la fórmula (I) es un estereoisómero individual o cualquier mezcla de estereoisómeros. 2.- La sal de potasio cristalina de acuerdo con la reivindicación 1, en donde R1 es -O- y R2 es fenilo opcionalmente sustituido con uno o varios sustituyentes seleccionados de flúor, cloro y yodo. 3.- La sal de potasio cristalina de acuerdo con la reivindicación 2 que tiene la fórmula:como un estereoisómero individual o cualquier mezcla de estereoisómeros.
CO09057912A 2006-12-04 2009-06-04 Sal de potasio cristalina de analogos de lipoxina a4 CO6190608A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87283006P 2006-12-04 2006-12-04

Publications (1)

Publication Number Publication Date
CO6190608A2 true CO6190608A2 (es) 2010-08-19

Family

ID=39076610

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09057912A CO6190608A2 (es) 2006-12-04 2009-06-04 Sal de potasio cristalina de analogos de lipoxina a4

Country Status (29)

Country Link
US (2) US7906678B2 (es)
EP (2) EP3489214A1 (es)
JP (1) JP5410984B2 (es)
KR (3) KR20160054030A (es)
CN (1) CN101553456B (es)
AR (1) AR064116A1 (es)
AU (1) AU2007327765B2 (es)
BR (1) BRPI0719679A2 (es)
CA (1) CA2670791C (es)
CL (1) CL2007003468A1 (es)
CO (1) CO6190608A2 (es)
CR (1) CR10837A (es)
DO (1) DOP2009000130A (es)
EA (1) EA018615B1 (es)
EC (1) ECSP099380A (es)
HK (1) HK1135961A1 (es)
IL (1) IL198434A (es)
MA (1) MA31079B1 (es)
MX (1) MX2009005911A (es)
MY (1) MY147951A (es)
NO (1) NO20092528L (es)
NZ (1) NZ577338A (es)
PE (2) PE20081200A1 (es)
SV (1) SV2009003286A (es)
TN (1) TN2009000167A1 (es)
TW (1) TWI415833B (es)
UY (1) UY30755A1 (es)
WO (1) WO2008068041A1 (es)
ZA (1) ZA200904689B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20081200A1 (es) * 2006-12-04 2008-11-06 Bayer Schering Pharma Ag Sal de potasio cristalina de analogos de lipoxina a4
US20090036530A1 (en) * 2006-12-04 2009-02-05 Bayer Schering Pharma Aktiengesellschaft Crystalline acid of lipoxin A4 analogs and method of making
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
AU2010286681A1 (en) * 2009-08-27 2012-02-09 Merck Sharp & Dohme Corp. Processes for preparing protease inhibitors of hepatitis C virus
WO2014130068A1 (en) 2013-02-21 2014-08-28 Forsyth Dental Infirmary For Children Methods for increasing oral ostenogenesis using lipoxin a4 (lxa4) and its analogs
WO2016149582A1 (en) * 2015-03-18 2016-09-22 The Forsyth Institute Methods for stabilizing atherosclerotic plaques using lipoxins, resolvins, and analogs thereof
CN109562186B (zh) 2016-06-03 2022-09-13 西蒂斯制药有限责任公司 与专门促消退介质的盐有关的组合物和方法
JP2020507761A (ja) 2017-01-31 2020-03-12 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 炎症系疾患の生化学的エンドタイプを定義するａｌｘ受容体リガンド
CN111875530A (zh) * 2020-08-17 2020-11-03 浙江朗华制药有限公司 一种普拉西坦水合物晶体及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650435A (en) * 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
DK0703897T3 (da) 1993-06-15 2008-12-01 Brigham & Womens Hospital Lipoxinforbindelser med forlænget halveringstid
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US5441951A (en) * 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
WO1995001179A1 (en) 1993-06-29 1995-01-12 Brigham & Women's Hospital Modulation of inflammation related to columnar epithelia
US6008205A (en) 1997-04-04 1999-12-28 The Brigham & Women's Hospital, Inc. Polyisoprenyl phosphate stable analogs for regulation of neutrophil responses
US6236978B1 (en) * 1997-11-14 2001-05-22 New York University System and method for dynamic profiling of users in one-to-one applications
US6006466A (en) * 1998-08-20 1999-12-28 Washecka; John Concealed linear payout holder for fishing leader
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
DK1165066T3 (da) 1999-03-18 2006-03-06 Brigham & Womens Hospital Anvendelse af lipoxin-forbindelser til inhibering af TNF-alfa-initieret neutrofil respons
JP2002539181A (ja) 1999-03-18 2002-11-19 ブリガム・アンド・ウイメンズ・ホスピタル リポキシン化合物およびこれらの使用
AU780114B2 (en) 1999-03-18 2005-03-03 Brigham And Women's Hospital Regulation of phospholipase D activity
DK1237549T3 (da) 1999-11-09 2004-06-07 Alcon Inc Lipoxin A4 og dets analoger til behandling af törre öjne
AU2001249329A1 (en) 2000-03-20 2001-10-03 Brigham And Women's Hospital Lipoxin analogs and methods for the treatment of periodontal disease
US6831186B2 (en) * 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs
AU2002347539A1 (en) 2001-12-13 2003-06-23 Ranbaxy Laboratories Limited Crystalline cefdinir potassium dihydrate
WO2003078425A1 (en) 2002-03-15 2003-09-25 Dr. Reddy's Laboratories Limited Novel crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt
ATE487478T1 (de) 2003-01-30 2010-11-15 Lek Pharmaceuticals Herstellung eines neuen pharmazeutisch geeigneten losartan-salzes und von seinen formen mittels neuer reinigungs- und isolationsverfahren
WO2006035291A1 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Crystalline forms of cefdinir potassium
US7223718B2 (en) * 2005-03-07 2007-05-29 Falcon Lab Llc Enhanced glyphosate herbicidal concentrates
KR20070088764A (ko) 2005-10-31 2007-08-29 테바 파마슈티컬 인더스트리즈 리미티드 세프디니어 칼륨염의 결정형
PE20081200A1 (es) * 2006-12-04 2008-11-06 Bayer Schering Pharma Ag Sal de potasio cristalina de analogos de lipoxina a4

Also Published As

Publication number Publication date
WO2008068041A1 (en) 2008-06-12
US20110124910A1 (en) 2011-05-26
CN101553456B (zh) 2013-08-28
IL198434A (en) 2012-09-24
US20080182897A1 (en) 2008-07-31
MX2009005911A (es) 2009-09-07
ECSP099380A (es) 2009-11-30
AR064116A1 (es) 2009-03-11
CL2007003468A1 (es) 2008-07-04
KR20090101169A (ko) 2009-09-24
HK1135961A1 (en) 2010-06-18
TN2009000167A1 (en) 2010-10-18
CN101553456A (zh) 2009-10-07
IL198434A0 (en) 2010-02-17
EA018615B1 (ru) 2013-09-30
UY30755A1 (es) 2008-07-31
AU2007327765A1 (en) 2008-06-12
EP3489214A1 (en) 2019-05-29
US7906678B2 (en) 2011-03-15
PE20120395A1 (es) 2012-05-23
TW200838847A (en) 2008-10-01
NZ577338A (en) 2011-02-25
JP2010511649A (ja) 2010-04-15
CA2670791A1 (en) 2008-06-12
CA2670791C (en) 2017-01-03
EA200900732A1 (ru) 2009-12-30
DOP2009000130A (es) 2009-08-15
EP2089350B1 (en) 2018-08-22
MA31079B1 (fr) 2010-01-04
BRPI0719679A2 (pt) 2014-01-14
EP2089350A1 (en) 2009-08-19
US8049035B2 (en) 2011-11-01
ZA200904689B (en) 2011-10-26
AU2007327765B2 (en) 2012-04-12
NO20092528L (no) 2009-08-26
MY147951A (en) 2013-02-15
JP5410984B2 (ja) 2014-02-05
CR10837A (es) 2009-07-23
SV2009003286A (es) 2009-10-02
KR20140135847A (ko) 2014-11-26
TWI415833B (zh) 2013-11-21
PE20081200A1 (es) 2008-11-06
KR20160054030A (ko) 2016-05-13

Similar Documents

Publication Publication Date Title
CO6190608A2 (es) Sal de potasio cristalina de analogos de lipoxina a4
CY1113716T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
UY32606A (es) Sulfonamidas nematocidas
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
UY29388A1 (es) Derivados del (1,5-difenil-h-pirazol-3-il)oxadiazol, su preparación y su aplicacion en terapéutica.
CR8475A (es) Fenilalanina-amidas sustituidas por benzoilo
RS52870B (en) INHIBITOR PROLIL HYDROXYLASE
AR084362A1 (es) Amidas de aminoindano que tienen una alta actividad fungicida y sus composiciones fitosanitarias
ATE542798T1 (de) Organische verbindungen
CY1112705T1 (el) Συντηγμενες κυκλικες ενωσεις
CO6241076A2 (es) Compuestos de benzamida y aplicaciones de los mismos
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
EA200802380A1 (ru) Совместные кристаллы пирролидинонов
PE20091843A1 (es) Inhibidores de catepsina c
CY1112829T1 (el) Νεα μεθοδος συνθεσης για την αγομελατινη
UY30387A1 (es) Nuevos compuestos
AR058445A1 (es) Un aditivo mejorador de asfalto y un cemento asfaltico y mezcla asfaltica que contienen al aditivo
ES2557477T3 (es) Nuevos compuestos peptídicos cíclicos
CY1115094T1 (el) Νεα μεθοδος για την συνθεση (7-μεθοξυ-1-ναφθυλ) ακετονιτριλιου και εφαρμογη στην συνθεση αγομελατινης
CR11463A (es) Compuestos de piridilmetil-sulfonamida
MX2009012338A (es) Compuestos organicos de azufre y su uso para controlar artropodos dañinos.
PE20090703A1 (es) Nuevo procedimiento de sintesis del ranelato de estroncio y de sus hidratos
CO6251235A2 (es) Compuestos derivados de azetidinas su preparacion y su aplicacion en terapeutica
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины

Legal Events

Date Code Title Description
FC Application refused